

Monica Bellei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1363509/publications.pdf>

Version: 2024-02-01

53
papers

5,319
citations

236912

25
h-index

197805

49
g-index

53
all docs

53
docs citations

53
times ranked

4535
citing authors

#	ARTICLE	IF	CITATIONS
1	Follicular Lymphoma International Prognostic Index. <i>Blood</i> , 2004, 104, 1258-1265.	1.4	1,552
2	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. <i>Journal of Clinical Oncology</i> , 2009, 27, 4555-4562.	1.6	613
3	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. <i>Blood</i> , 2004, 103, 2474-2479.	1.4	549
4	Early Positron Emission Tomography Responseâ€“Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1786-1794.	1.6	397
5	Omitting Radiotherapy in Early Positron Emission Tomographyâ€“Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1188-1194.	1.6	349
6	Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project. <i>Journal of Clinical Oncology</i> , 2013, 31, 240-246.	1.6	287
7	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	1.6	143
8	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. <i>Blood</i> , 2018, 131, 1456-1463.	1.4	130
9	Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3019-3025.	1.6	129
10	Watchful Waiting in Lowâ€“Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. <i>Journal of Clinical Oncology</i> , 2012, 30, 3848-3853.	1.6	107
11	High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkinâ€™s Lymphoma Responding to Front-Line Therapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 2320-2325.	1.6	106
12	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	3.5	90
13	High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. <i>Haematologica</i> , 2009, 94, 146-148.	3.5	66
14	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2018, 132, 179-186.	1.4	63
15	Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. <i>Hematological Oncology</i> , 2007, 25, 189-197.	1.7	49
16	Peripheral T cell lymphoma, not otherwise specified (PTCLâ€“NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.	2.5	49
17	Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011, 29, 4227-4233.	1.6	47
18	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	4.1	43

#	ARTICLE	IF	CITATIONS
19	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. <i>British Journal of Haematology</i> , 2018, 183, 755-765.	2.5	41
20	Concerning the mechanism of increased thermogenesis in rats treated with dehydroepiandrosterone. <i>Journal of Bioenergetics and Biomembranes</i> , 1993, 25, 313-321.	2.3	38
21	Prognostic relevance of serum λ 2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISSI study. <i>Haematologica</i> , 2007, 92, 1482-1488.	3.5	38
22	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. <i>Haematologica</i> , 2017, 102, 1748-1757.	3.5	38
23	T-Cell Lymphomas in South America and Europe. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 34, 42-47.	0.7	38
24	Changes in Liver Structure and Function after Short-Term and Long-Term Treatment of Rats with Dehydroepiandrosterone. <i>Journal of Nutrition</i> , 1992, 122, 967-976.	2.9	34
25	Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2016, 172, 879-888.	2.5	29
26	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020, 9, 6565-6575.	2.8	29
27	Induction of Thermogenic Enzymes by DHEA and Its Metabolites. <i>Annals of the New York Academy of Sciences</i> , 1995, 774, 171-179.	3.8	27
28	The Effects of the Ergosteroid 7-Oxo-dehydroepiandrosterone on Mitochondrial Membrane Potential: Possible Relationship to Thermogenesis. <i>Archives of Biochemistry and Biophysics</i> , 1997, 341, 122-128.	3.0	26
29	Follicular lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 34, 54-59.	0.7	24
30	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011, 52, 823-832.	1.3	23
31	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. <i>Blood Advances</i> , 2021, 5, 640-648.	5.2	22
32	Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-cell Project, an international, cooperative study. <i>Hematological Oncology</i> , 2017, 35, 630-636.	1.7	19
33	Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry. <i>Hematological Oncology</i> , 2015, 33, 147-151.	1.7	16
34	First Report On the H10 EORTC/GELA/IL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin's Lymphoma, for the Groupe d'Etude Des Lymphomes De l'Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2009, 114, 97-97.	1.4	16
35	Prognostic factors in low-grade non-Hodgkin lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 202-210.	2.3	13
36	Incidence Clinical Characteristics and Survival of Non Splenic Marginal Zone Lymphomas: A Population Based Study from a Cancer Registry in Northern Italy. <i>Blood</i> , 2008, 112, 3753-3753.	1.4	13

#	ARTICLE	IF	CITATIONS
37	PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup. <i>Blood</i> , 2017, 130, 736-736.	1.4	11
38	The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 448-455.	2.3	10
39	BEACOPP or no BEACOPP?. <i>Lancet Oncology</i> , The, 2013, 14, e487-e488.	10.7	9
40	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective International T-Cell Project. <i>Haematologica</i> , 2019, 104, e178.2-e178.	3.5	7
41	Effect of cardiolipin on functional properties of isolated rat liver mitochondria. <i>IUBMB Life</i> , 1997, 41, 469-480.	3.4	6
42	Comparative studies of effects of dehydroepiandrosterone on rat and chicken liver. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1993, 105, 643-647.	0.2	5
43	Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study. <i>Blood</i> , 2010, 116, 432-432.	1.4	5
44	CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8552-8552.	1.6	4
45	Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project.. <i>Blood</i> , 2012, 120, 2650-2650.	1.4	3
46	T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2009, 31, .	0.7	2
47	Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial. <i>Blood</i> , 2016, 128, 184-184.	1.4	2
48	The Outcome of T-Cell Lymphoma Patients Failing First-Line Treatment: Results of a Population Based-Study From the Modena Cancer Registry. <i>Blood</i> , 2012, 120, 1611-1611.	1.4	1
49	The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. <i>Blood</i> , 2016, 128, 921-921.	1.4	1
50	When should a watch-and-wait strategy be adopted for follicular lymphoma?. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 91-94.	1.6	0
51	A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2004, 104, 3261-3261.	1.4	0
52	Incidence, Clinical Characteristics and Survival of Malignant Lymphomas in the Province of Modena (Italy); a Population-Based Study.. <i>Blood</i> , 2006, 108, 4628-4628.	1.4	0
53	Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007, 110, 3432-3432.	1.4	0